About this webinar
Life sciences manufacturers are under growing pressure to improve efficiency, ensure data integrity, and remain inspection-ready—while managing increasingly complex GxP requirements. Yet many digital initiatives fail due to high cost, long timelines, or lack of alignment between Operations, QA, and IT.
In this webinar, we cut through the theory and focus on how Digital GxP Operations work in real manufacturing environments, using Manufacturing Execution Systems (MES) and Electronic Batch Records (EBR) as proven foundations.
You’ll gain clear, experience-based guidance on where to start, what delivers fast ROI, and how to avoid common MES and EBR pitfalls—supported by a real-world case study.
What You’ll Learn
1.Why Digital GxP Operations Matter Now
Understand the industry trends, regulatory pressure, and business risks making digital GxP operations a necessity—not an option.
2. The Role of MES and EBR in GxP Manufacturing
Learn how MES and EBR enable process control, traceability, and inspection-ready manufacturing in regulated environments.
3. Practical GxP Challenges Solved by MES & EBR
Explore how MES-driven EBR addresses common issues with paper and legacy systems—improving compliance, efficiency, and data integrity.
4. Implementation Reality: What Successful Companies Do
Discover proven approaches for starting small, aligning Operations, QA, and IT, and delivering value without over-engineering.
5. Lessons Learned: Fast-Track Implementation at SCHOTT MINIFAB
A real case study showing rapid deployment, measurable ROI, and tangible operational impact.
Watch the webinar
by filling out the form
Meet our speaker
Orchun Thakral, Head of Customer Success & Sales Director at BatchLine, brings 15 years of expertise in Technical, Sales, and Management roles within the Pharma/Bio industry.
He has extensive experience in highly regulated GMP environments, specializing in Manufacturing Execution Systems (MES) and Electronic Batch Records (EBR).
His background spans traditional pharmaceuticals, biotechnology, vaccines, blood plasma, and innovative cell and gene therapy processes.
